Skullcandy ANC Earbuds Tuned by Bose Are Going for Peanuts, a Great Budget Alternative to Bose
Skullcandy and Bose combined forces on these Amazon's Choice-winning wireless earbuds, bringing the distinctive Bose sound to the comfort, accessibility, and distinctive design of Skullcandy's earbuds. The Skull-iQ app controls the Method ANC earbuds and lets you do everything from choose a preset EQ to reconfiguring the button functions on the buds themselves. Even with active noise cancellation turned on, the Method 360 ANC buds give you an amazing 32 hours of battery life (9 in the buds, 23 in the charging case).
See at Amazon
No matter what brand name is on the label, Sound by Bose always means pro-level high fidelity sound that comes through crystal clear with immersive depth of range. The Skullcandy Method 360 ANC earbuds are tuned and optimized to meet Bose's lofty standards, with three preset EQs you can access through the Skull-iQ app, or you can create one of your own once you hit the perfect balance for you.
The active noise cancellation in the Skullcandy Method 360 buds is also top notch, with four mics picking up and eliminating the sounds of your surroundings. There's a Stay Aware mode that gives you the option of disappearing completely into your music or podcast, or letting in enough of your surroundings to be safe and alert. Either bud can be worn solo, and the Method 360 buds also feature multipoint pairing, Google Fast Pair, and Auto On/Connect. They work equally well when paired with iPhones or Android phones.
The distinctive Skullcandy charging case has a built-in look and metal ring perfect for being clipped anywhere — lanyards, carabiners, inside hooks in backpacks or briefcases, anywhere that's most convenient for you, knowing the Method 360 buds are safely secured and within reach. With IPX4 sweat and water resistance making them the ideal workout buds, clipping them to your gym bag is a natural fit.
Premium Bose sound does not always have to come with the premium price tag that often accompanies Bose wireless earbuds. The Skullcandy Method 360 buds are the product of an awesome collaboration with Bose, and when you factor in Amazon's 27% off deal that drops the price from an already accessible $130 to a bargain $95, it's the best price point to find that Bose sound.
See at Amazon
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
42 minutes ago
- Yahoo
ViroCell Biologics and AvenCell Therapeutics Announce Retroviral Vector Manufacturing Collaboration to Accelerate Development of Novel Allogeneic CAR-T Therapies for Blood Cancers
AvenCell selected ViroCell for retroviral vector CDMO services to drive its pipeline of innovative allogeneic CAR T-cell therapies, based on ViroCell's deep expertise and track record. LONDON & NEW YORK, July 29, 2025--(BUSINESS WIRE)--ViroCell Biologics ("ViroCell"), a specialist viral vector Contract Development and Manufacturing Organisation ("CDMO") for cell and gene therapy (CGT) clinical trials, announces a manufacturing collaboration with and the successful delivery of a novel retroviral vector to AvenCell Therapeutics, Inc. ("AvenCell"), a leading clinical-stage cell therapy company focused on advancing allogeneic switchable CAR-T cell therapies. This first retroviral vector will be used to manufacture AVC-203, an investigational CD19/CD20 dual-targeted cell therapy for the treatment of B cell malignancies and autoimmune diseases. AvenCell's AV203 is its second investigational cell therapy using its differentiated allogeneic engineering to provide an "off-the-shelf" product engineered to overcome graft-versus-host disease as well as graft rejection by host T and Natural Killer ("NK") cells. AVC-203 is designed to achieve superior efficacy compared to currently-approved CAR-Ts while enabling immediate treatment and greater patient access at much lower cost and complexity. The further inclusion of AvenCell's RevCAR™ receptor in AVC203 allows for additional antigen targeting (with "off/on" capability in vivo) beyond CD19 and CD20. AvenCell selected ViroCell as its partner to manufacture the retroviral vector for this program based on the CDMO's expertise and track record in delivering high yield vectors at speed. Incorporating a cell line acquired by AvenCell into the GMP manufacturing process, ViroCell successfully delivered a high yield vector while meeting AvenCell's accelerated timeline. This program evidences ViroCell's ability to deliver a bespoke, complex manufacturing process in the allogeneic CAR-T cell therapy space, ultimately, enabling AvenCell's timelines for clinical entry. AvenCell's AVC-203 is expected to enter a first-in-human phase I study in patients with relapsed/refractory B cell lymphoma in H2/2025. John W. Hadden II, CEO of ViroCell, commented: "We are thrilled to partner with AvenCell and support their innovative allogeneic CAR-T therapy platform. I am proud of Team ViroCell's accomplishments on the successful end-to-end delivery of this retroviral vector and accelerating a novel therapy into clinical development in an area of high unmet need. We look forward to continuing our work with AvenCell on their exciting platform." Andrew Schiermeier, Ph.D., CEO, AvenCell, added: "We are delighted with ViroCell's performance in process development and GMP manufacture of this complex retroviral vector. We selected ViroCell to support our platform because we knew that they could execute reliably in areas where other CDMOs can't. The delivery of this retroviral vector for AVC-203 is proof that our trust in ViroCell was well placed." Notes to editor: ViroCell ViroCell Biologics is an innovation-driven Contract Development and Manufacturing Organization ("CDMO") focused exclusively on the design, de-risking, and GMP manufacture of viral vectors for clinical trials. Built around one of the most prolific academic viral vector manufacturing teams, ViroCell was created to address the global demand for precisely engineered viral vectors. The team leverages its deep track record to help clients to de-risk and accelerate novel cell and gene therapies into and through clinical development, with a mission of being the partner of choice for corporate and academic innovators. Focused initially on manufacturing lentiviral and retroviral vectors, ViroCell enables clients to start clinical trials on a scalable platform, delivering value by reducing costs, time and regulatory risk. AvenCell Therapeutics AvenCell derives its name from the French word "avenir" to reflect the aim to be the FUTURE of cell therapy. AvenCell is building a truly transformative cell therapy company that targets difficult-to-treat cancers, with its lead programs focusing on acute myeloid leukemia (AML) and additional programs targeting other hematological malignancies. AvenCell was formed with the goal to create truly allogeneic cells that persist as long or longer than autologous therapies and develop a universal and switchable construct that allows complete control and target redirection of T cells after they are infused into a patient. Integration of these two platforms allows for complete separation of the manufacturing of cells from ultimate patient and cancer target, thus providing significant scalability potential at orders of magnitude more efficient than current approaches. AvenCell Therapeutics, Inc. was launched in 2021 by Blackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics. AvenCell is headquartered in Watertown, Massachusetts with additional R&D and manufacturing operations in Dresden, Germany. View source version on Contacts For more information, please contact: ViroCell John W. Hadden II, CEOinfo@ For media enquiries, please contact: ViroCell – FTI Consulting Simon Conway / Tim StamperViroCell@ +44 (0)20 3727 1000 AvenCell – H Advisors Emma +1 (917) 763-6685 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
Yahoo
42 minutes ago
- Yahoo
Highest Dividend Strategy: What Makes Horizon Technology Finance Corporation (HRZN) Stand Out
Horizon Technology Finance Corporation (NASDAQ:HRZN) is included among the 10 Stocks with Highest Dividend to Buy Right Now. A financial adviser looking over a portfolio of securities and stocks. Horizon Technology Finance Corporation (NASDAQ:HRZN) is a specialty finance firm that provides loans and makes investments in early-stage companies operating in sectors like technology, life sciences, healthcare information and services, and clean technology — collectively known as its Target Industries. In the first quarter of 2025, Horizon Technology Finance Corporation (NASDAQ:HRZN) reported net investment income of $0.27 per share, reflecting its ongoing commitment to sustaining shareholder distributions. Despite facing broader economic headwinds, it expanded its debt portfolio by $20 million during the quarter. Horizon Technology Finance Corporation (NASDAQ:HRZN) also boosted its committed and approved investment pipeline to $236 million, laying a solid foundation for continued portfolio growth. CFO Dan Trolio highlighted the company's strong financial position, noting $126 million in available liquidity, including $77 million in cash and $49 million accessible through credit lines. The company maintained a debt-to-equity ratio of 1.54:1, with net leverage at 1.29:1. Horizon Technology Finance Corporation (NASDAQ:HRZN) is among the best stocks with the highest dividend, maintaining its payouts for 16 consecutive years. The company currently offers a monthly dividend of $0.11 per share for a dividend yield of 15.94%, as of July 27. While we acknowledge the potential of HRZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None.
Tom's Guide
43 minutes ago
- Tom's Guide
Deal confirmed — the PS5 Slim Digital Edition bundled with Call of Duty: Black Ops 6 is down to AU$569 right now
In what is probably the best console deal you'll find this side of Black Friday, Amazon has slashed the price of the PS5 Slim Digital Edition's Call of Duty: Black Ops 6 bundle, bringing the console down to its current best price. Right now, you can grab the aforementioned console and game combo for just AU$569 — that's an incredible saving of AU$180.95 on the bundle's AU$749 RRP, and even cheaper than Amazon's price on the standalone PS5 Slim Digital Edition console. Our Black Ops 6 review cited the game as having "the franchise's best multiplayer in years", and while the game will be superseded by Black Ops 7 later this year, you can always use this bundle to sharpen your skills before the new game drops. Score a fantastic deal on this bundle, featuring the disc-free PS5 Slim and a digital copy of Call of Duty: Black Ops 6. This is currently the best price available for those who prefer digital media. That said, if you love physical media, the PS5 Slim Disc Edition is available for AU$699, down from AU$829.95. Worried about it being the disc-free version of the console? Don't fret — the PS5 Slim's modular design means you can always purchase the PS5 Disc Drive at a later date. At present, Amazon is selling the PS5 Disc Drive for AU$124. Alternatively, you could opt to buy the PS5 Slim Disc Edition for AU$699 — a saving of AU$130.95 from its usual price of AU$829.95. So if you're in the market for a new game console and a killer game to play on it, it's hard to go past either of these bundles.
